Home » Stocks » SRTS

Sensus Healthcare, Inc. (SRTS)

Stock Price: $3.66 USD 0.28 (8.28%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $3.65 -0.01 (-0.27%) Apr 16, 6:09 PM
Market Cap 60.34M
Revenue (ttm) 9.58M
Net Income (ttm) -6.84M
Shares Out 16.43M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE 357.14
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $3.66
Previous Close $3.38
Change ($) 0.28
Change (%) 8.28%
Day's Open 3.38
Day's Range 3.22 - 3.73
Day's Volume 67,471
52-Week Range 1.76 - 6.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a  medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effectiv...

1 month ago - GlobeNewsWire

Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices Patent covers beam splitting and sculpting capabilit...

1 month ago - GlobeNewsWire

BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective...

3 months ago - GlobeNewsWire

Sensus Healthcare' (SRTS) CEO Joe Sardano on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

5 months ago - GlobeNewsWire

BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective ...

5 months ago - GlobeNewsWire

BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...

5 months ago - GlobeNewsWire

Sensus Healthcare' (SRTS) CEO Joe Sardano on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

8 months ago - GlobeNewsWire

Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems

8 months ago - GlobeNewsWire

Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state

8 months ago - GlobeNewsWire

BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological a...

8 months ago - GlobeNewsWire

BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effect...

8 months ago - GlobeNewsWire

BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...

9 months ago - GlobeNewsWire

BOCA RATON, Fla. , June 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and...

9 months ago - GlobeNewsWire

BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non...

9 months ago - GlobeNewsWire

June 18 Event is the Third in a Series of Topical Discussions

10 months ago - GlobeNewsWire

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT

1 year ago - GlobeNewsWire

Sensus Healthcare's (SRTS) CEO Joe Sardano on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BOCA RATON, Fla, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effectiv...

1 year ago - GlobeNewsWire

New corporate structure positions company for 2020 financial goals

1 year ago - GlobeNewsWire

BOCA RATON, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effe...

1 year ago - GlobeNewsWire

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Sensus Healthcare's (SRTS) CEO Joe Sardano on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Sensus Healthcare's (SRTS) CEO Joe Sardano on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Today, we look at a small medical device maker based in South Florida.

1 year ago - Seeking Alpha

About SRTS

Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and do... [Read more...]

Industry
Medical Devices
IPO Date
Jun 3, 2016
CEO
Joseph Sardano
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
SRTS
Full Company Profile

Financial Performance

In 2020, SRTS's revenue was $9.58 million, a decrease of -64.87% compared to the previous year's $27.26 million. Losses were -$6.84 million, 302.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SRTS stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 83.33% from the latest price.

Price Target
$6.71
(83.33% upside)
Analyst Consensus: Buy